文献速递心脏核医学

18F-FDG PET显像监测急性心肌梗死的抗炎治疗:探索MCC950在小鼠模型中的作用

18F-FDG PET imaging-monitored anti-inflammatory therapy for acute myocardial infarction: Exploring the role of MCC950 in murine model.
PubMed 文献 · J Nucl Cardiol · 2020-02-03

本研究在小鼠急性心肌梗死(AMI)模型中,用18F-FDG PET显像监测NLRP3炎症小体抑制剂MCC950的抗炎疗效。结果显示,MCC950治疗组梗死区第3天和第5天的18F-FDG炎症摄取低于心肌梗死组,且MCC950减轻了存活缺损的扩大;急性期FDG-PET炎症信号与晚期存活缺损及左心室射血分数(LVEF)下降正相关。作者认为18F-FDG PET显像在MCC950的临床转化中具有应用潜力。

要点

  • MCC950治疗组梗死区第3天和第5天的18F-FDG炎症摄取低于心肌梗死组。
  • MCC950显著减轻存活缺损的扩大,提示其心肌保护作用。
  • 急性期FDG-PET炎症信号与晚期存活缺损及LVEF下降正相关。

核心结论

  • 作者用18F-FDG PET显像无创地显示了MCC950在急性心肌梗死中的治疗效果,并认为18F-FDG PET显像在MCC950的临床转化中具有应用潜力。

研究设计与样本

  • C57BL/6小鼠构建急性心肌梗死模型,术后1小时腹腔注射MCC950或无菌生理盐水,随后连续7天每日给药。
  • 第3天和第5天行18F-FDG PET(炎症)显像监测炎症变化,并用免疫组化和Western blot检测炎症标志物以验证PET结果。
  • 第7天和第28天行18F-FDG PET(存活)显像定量存活缺损扩大,并行心脏超声与生存分析评估心功能与生存率。
  • 用麦胚凝集素(WGA)和Masson三色染色判定不良重构。

主要发现

  • FDG-PET(炎症)显像显示,MCC950治疗组梗死区第3天和第5天的18F-FDG炎症摄取低于心肌梗死组。
  • MCC950组M1巨噬细胞和中性粒细胞浸润减少、NLRP3/IL-1β通路缓解,证实了FDG-PET(炎症)显像结果。
  • FDG-PET(存活)显像显示MCC950显著减轻存活缺损的扩大,显示其心肌保护作用。
  • 急性期FDG-PET(炎症)信号与晚期存活缺损及左心室射血分数(LVEF)下降正相关。
  • MCC950减轻不良重构并改善生存率,进一步支持其在急性心肌梗死中的抗炎效果。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: MCC950 is a novel NLRP3 inflammasome inhibitor that possesses potent anti-inflammatory properties in acute myocardial infarction (AMI). However, the lack of noninvasive monitoring methods limits its potential clinical translation. Thus, we sought to investigate whether 18F-FDG PET imaging can monitor the therapeutic effects of MCC950 in an AMI murine model. METHODS: C57BL/6 mice were used to generate an AMI model. MCC950 or sterile saline was intraperitoneally administered 1 hour after surgery and then daily for 7 consecutive days. 18F-FDG PET (inflammation) imaging was used to monitor inflammatory changes on days 3 and 5. Immunohistochemistry and Western blot were used to detect inflammatory markers and to confirm the PET imaging results. 18F-FDG PET (viability) imaging was used to quantitate the viability defect expansion on days 7 and 28. Cardiac ultrasound and survival analyses were performed to evaluate the cardiac function and survival rate. Adverse remodeling was determined by Wheat Germ Agglutinin (WGA) and Masson trichrome staining. RESULTS: The FDG-PET (inflammation) imaging revealed that MCC950 treatment led to lower 18F-FDG inflammatory uptakes, at the infarct region, on days 3 and 5 when compared to the MI group. The decreased M1 macrophages and neutrophils infiltration and the remission of the NLRP3/IL-1β pathway, confirmed the FDG-PET (inflammation) imaging results. The FDG-PET (viability) imaging revealed that MCC950 significantly decreased the expansion of the viability defect, demonstrating its myocardial preservation effects. The acute FDG-PET (inflammation) signal positively correlated with the late viability defect and with the reduction in the left ventricular ejection fraction (LVEF). Additionally, the alleviated adverse remodeling and the improved survival rate further support the anti-inflammatory efficiency of MCC950 in AMI. CONCLUSION: Using 18F-FDG PET imaging, we noninvasively demonstrated the therapeutic effects of MCC950 in AMI and showed that 18F-FDG PET imaging holds promising application potentials in MCC950's clinical translation.

来源:J Nucl Cardiol,查看原文。版权归原作者所有。

引用

  1. Li X, Yang W, Ma W, et al. 18F-FDG PET imaging-monitored anti-inflammatory therapy for acute myocardial infarction: Exploring the role of MCC950 in murine model. J Nucl Cardiol. 2020. PMID: 32016690. doi:10.1007/s12350-020-02044-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。